17-16940445-A-C
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM1PP3_StrongPP5
The NM_012452.3(TNFRSF13B):c.512T>G(p.Leu171Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000172 in 1,614,020 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00014 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00018 ( 0 hom. )
Consequence
TNFRSF13B
NM_012452.3 missense
NM_012452.3 missense
Scores
9
4
6
Clinical Significance
Conservation
PhyloP100: 1.69
Genes affected
TNFRSF13B (HGNC:18153): (TNF receptor superfamily member 13B) The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
PM1
In a transmembrane_region Helical; Signal-anchor for type III membrane protein (size 20) in uniprot entity TR13B_HUMAN there are 4 pathogenic changes around while only 0 benign (100%) in NM_012452.3
PP3
MetaRNN computational evidence supports a deleterious effect, 0.964
PP5
Variant 17-16940445-A-C is Pathogenic according to our data. Variant chr17-16940445-A-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 440340.We mark this variant Likely_pathogenic, oryginal submissions are: {Pathogenic=1, Likely_pathogenic=2, Uncertain_significance=4}. Variant chr17-16940445-A-C is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TNFRSF13B | NM_012452.3 | c.512T>G | p.Leu171Arg | missense_variant | 4/5 | ENST00000261652.7 | NP_036584.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TNFRSF13B | ENST00000261652.7 | c.512T>G | p.Leu171Arg | missense_variant | 4/5 | 1 | NM_012452.3 | ENSP00000261652 | P2 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152210Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
21
AN:
152210
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000104 AC: 26AN: 250756Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135592
GnomAD3 exomes
AF:
AC:
26
AN:
250756
Hom.:
AF XY:
AC XY:
14
AN XY:
135592
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000176 AC: 257AN: 1461692Hom.: 0 Cov.: 31 AF XY: 0.000162 AC XY: 118AN XY: 727140
GnomAD4 exome
AF:
AC:
257
AN:
1461692
Hom.:
Cov.:
31
AF XY:
AC XY:
118
AN XY:
727140
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000138 AC: 21AN: 152328Hom.: 0 Cov.: 33 AF XY: 0.000161 AC XY: 12AN XY: 74494
GnomAD4 genome
AF:
AC:
21
AN:
152328
Hom.:
Cov.:
33
AF XY:
AC XY:
12
AN XY:
74494
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
12
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Blueprint Genetics | Mar 22, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2018 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 07, 2024 | Published functional studies demonstrate unstable protein with negligible ligand binding (PMID: 21419480); Reported in an individual with lower respiratory track infections, HSV infections, and giardiasis; however her heterozygous mother was reportedly healthy and the variant did not segregate with autoimmunity, vitiligo, and thyroiditis in the extended family members (PMID: 22697072); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 17983875, 37711607, 35570134, 34247095, 32344018, 19779048, 23237420, 17392798, 31530980, 32581362, 21419480, 22697072) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 30, 2021 | PS3, PP3 - |
Immunodeficiency, common variable, 2 Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 25, 2022 | This sequence change replaces leucine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 171 of the TNFRSF13B protein (p.Leu171Arg). This variant is present in population databases (rs143027621, gnomAD 0.02%). This variant has been reported as homozygous, compound heterozygous, and heterozygous in individuals and families affected with common variable immunodeficiency (PMID: 17983875, 17392798, 19779048, 22697072, 23237420, 32581362, 31530980). It has also been observed as heterozygous in asymptomatic individuals from these same families (PMID: 23237420, 22697072). ClinVar contains an entry for this variant (Variation ID: 440340). ClinVar contains an entry for this variant (Variation ID: 440340). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TNFRSF13B protein function. Experimental studies have shown that this missense change affects TNFRSF13B function (PMID: 21419480). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Sep 09, 2022 | ACMG classification criteria: PS3 supporting, PM3 strong, PP3 supporting - |
not specified Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 03, 2017 | - - |
TNFRSF13B-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 13, 2024 | The TNFRSF13B c.512T>G variant is predicted to result in the amino acid substitution p.Leu171Arg. This variant has been reported in the homozygous, compound heterozygous and heterozygous states in individuals with common variable immunodeficiency (Castigli et al. 2007. PubMed ID: 17392798; Zhang et al. 2007. PubMed ID: 17983875; Martínez-Pomar et al. 2009. PubMed ID: 19779048; Barroeta Seijas et al. 2012. PubMed ID: 22697072; Martinez-Gallo et al. 2013. PubMed ID: 23237420). This variant has also been observed in the heterozygous state in asymptomatic individuals (Family of patient C.I - father C.II and sister C.III, Martinez-Gallo et al. 2013. PubMed ID: 23237420). The variant did not segregate with disease in another family with autoimmunity, vitiligo, and thyroiditis (Family C, Barroeta Seijas et al. 2012. PubMed ID: 22697072). Of note, in that family all members (mother, father, sister, and proband) were reported healthy, but had symptoms of autoimmune diseases; however only the proband was diagnosed with common variable immunodeficiency. Functional studies demonstrated that the p.Leu171Arg variant impacted the expression and function of the TNFRSF13B protein (Fried et al. 2011. PubMed ID: 21419480). This variant is reported in 0.019% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant has conflicting interpretations in the ClinVar database, ranging from pathogenic to likely pathogenic to uncertain significance (https://www.ncbi.nlm.nih.gov/clinvar/variation/440340/). While this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Benign
DEOGEN2
Uncertain
D;.
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Benign
T;T
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Uncertain
M;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Benign
T
PROVEAN
Pathogenic
D;.
REVEL
Pathogenic
Sift
Pathogenic
D;.
Sift4G
Uncertain
D;D
Polyphen
D;D
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at